Compare ASC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASC | ESPR |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.9M | 731.9M |
| IPO Year | 2013 | 2013 |
| Metric | ASC | ESPR |
|---|---|---|
| Price | $15.98 | $3.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $17.00 | $8.75 |
| AVG Volume (30 Days) | 713.6K | ★ 17.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $403,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.81 |
| P/E Ratio | $16.60 | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $9.18 | $0.85 |
| 52 Week High | $20.03 | $4.18 |
| Indicator | ASC | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 34.08 | 70.44 |
| Support Level | $14.91 | $3.11 |
| Resistance Level | $16.91 | $3.18 |
| Average True Range (ATR) | 0.73 | 0.01 |
| MACD | -0.44 | -0.02 |
| Stochastic Oscillator | 4.98 | 62.50 |
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The company markets its services directly to its customers and commercial pool operators and charters its vessels to them through a combination of spot, commercial pooling, and time-charter arrangements. The majority of its revenue is generated from spot voyages, which typically last less than three months.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.